Advertisement

Search Results

Advertisement



Your search for ,Per matches 3772 pages

Showing 1 - 50


lung cancer

SWOG S2302 Pragmatica-Lung Study Design Still Significant Even With Negative Results in Advanced NSCLC

Although the SWOG S2302 Pragmatica-Lung trial did not achieve its primary endpoint of improved overall survival with the combination of ramucirumab and pembrolizumab compared with standard-of-care treatments for patients with stage IV or recurrent non–small cell lung cancer (NSCLC) who previously...

skin cancer
immunotherapy

Dual Immunotherapy May Improve Progression-Free Survival in Advanced Squamous Cell Carcinoma

The combination of avelumab and cetuximab may improve progression-free survival in patients with advanced cutaneous squamous cell carcinoma compared with avelumab alone, according to recent findings presented by Zandberg et al at the 2025 ASCO Annual Meeting (Abstract 6002) and simultaneously...

multiple myeloma

Potential New Standard of Care Emerges in Multiple Myeloma

A new four-drug combination appears to be effective and safe in patients with newly diagnosed multiple myeloma, according to data from the ADVANCE clinical trial conducted by investigators at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine. Presented ...

colorectal cancer

ASCO 2025: Structured Exercise Program Improves Survival, Outcomes in Some Patients With Colon Cancer

A phase III study has found that a 3-year structured exercise program initiated soon after completion of adjuvant chemotherapy improves disease-free and overall survival, as well as patient-reported physical functioning and health-related fitness, in patients with stage III and high-risk stage II...

issues in oncology

ASCO 2025: Alcohol-Related Cancer Deaths Are on the Rise in the United States

A new study led by experts at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, is the first to look at trends over time in alcohol-linked cancer mortality across the United States. The findings were presented at the 2025 ASCO Annual Meeting (Abstract ...

lung cancer
immunotherapy

Harm-Benefit Balance of Immune Checkpoint Inhibitor Treatment in Non–Small Cell Lung Cancer

In a study reported in JAMA Oncology, Heyward et al examined the harm-benefit balance of immune checkpoint inhibitor use across lines of treatment in non–small cell lung cancer (NSCLC). Study Details The retrospective cohort study, conducted in 2024, involved 2013 to 2019 Surveillance,...

breast cancer
gynecologic cancers
issues in oncology

Climate Change and Risk for Breast and Gynecologic Cancers

Climate change may be contributing to a small but notable increase in the incidence and mortality rates of breast, ovarian, endometrial, and cervical cancers in the Middle East and North Africa, according to a recent study published by Mataria and Chun in Frontiers in Public Health. Background...

pancreatic cancer
issues in oncology

Alcohol May Be Linked to Higher Risk of Pancreatic Cancer

Investigators may have uncovered a modest but potentially significant association between alcohol consumption and the risk of developing pancreatic cancer, according to a recent study published by Naudin et al in PLOS Medicine. Background Pancreatic cancer is the twelfth most common cancer type...

leukemia

Mark Cuban Does It Again: Reshuffling the Deck of Front-Line CML Therapy

With the currently available BCR::ABL1 tyrosine kinase inhibitors, chronic myeloid leukemia (CML) has transformed from an invariably fatal disorder (10-year overall survival < 10%) to an indolent one, associated with a near-normal life expectancy on optimal tyrosine kinase inhibitor...

issues in oncology
solid tumors

Dose-Escalated Stereotactic Body Radiotherapy vs Conventional Radiotherapy for Painful Bone Metastases

In a Belgian phase III trial (ROBOMET) reported in the Journal of Clinical Oncology, Mercier et al attempted to determine whether dose-escalated, single-fraction stereotactic body radiotherapy was associated with statistically significant benefit vs conventional, single-fraction, 3D conformal...

issues in oncology

What Is the Value in Cost and Lives Saved of Cancer Screening and Prevention?

Several recent studies have shown the value of cancer screening in reducing the number of deaths from the disease. One study using computer modeling to estimate the number of cancer-related deaths that could be averted by increasing the use of U.S. Preventive Services Task Force (USPSTF)...

In Case You Missed It: Additional Abstracts of Interest in Cancer Research

Thousands of forward-looking research studies defined the 2025 American Association for Cancer Research (AACR) Annual Meeting. Here, aside from our fuller coverage of key presentations in The ASCO Post, we offer a snapshot of a few additional abstracts that may be of interest to cancer researchers...

hematologic malignancies
immunotherapy

Cellular Therapies Show Sustained Promise in Hematologic Malignancies, but Access Remains Uneven

Cellular therapies such as chimeric antigen receptor (CAR) T-cell therapy and tumor-infiltrating lymphocyte therapy are transforming outcomes for patients with cancer, particularly in the relapsed or refractory setting. “We’re seeing outstanding response rates in patients with B-cell malignancies...

breast cancer

Abbreviated MRI Scans in Detecting Breast Cancer for Women With Dense Breasts

Abbreviated breast MRI scans demonstrated comparable diagnostic accuracy to full multiparametric protocol MRI scans for women with extremely dense breasts, according to findings from the DENSE trial published in Radiology.   MRI scans have greater diagnostic accuracy than mammograms for women with...

issues in oncology

Antimicrobial Resistance in Outpatients With Cancer

In a U.S. multicenter retrospective cohort study reported in The Lancet Oncology, Gupta et al evaluated whether antimicrobial resistance was more common in pathogenic bacterial isolates from outpatients with cancer than in outpatients without cancer. Study Details The study involved data from the...

neuroendocrine tumors

FDA Approves First Oral Therapy for Pheochromocytoma and Paraganglioma

On May 14, the U.S. Food and Drug Administration approved the oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan (Welireg) for patients aged 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). This represents the first FDA ...

bladder cancer
thyroid cancer
gastroesophageal cancer
neuroendocrine tumors
colorectal cancer
lung cancer
lymphoma
multiple myeloma

NCCN Clinical Practice Guidelines in Oncology: 2025 Updates

The National Comprehensive Cancer Network (NCCN) released its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Today, guidelines are available for more than 60 tumor types, subtypes, and related topics. During the NCCN’s 30th Annual...

hematologic malignancies
solid tumors
issues in oncology
supportive care

GLP-1 Receptor Agonists Could Show Anticancer Benefits Beyond Weight Loss

First-generation weight-loss drugs like liraglutide and exenatide could show anticancer benefits beyond weight loss, according to findings from a retrospective, observational study presented by Sagy et al at the European Congress on Obesity (ECO) 2025 and simultaneously published in...

CRISPR-Cas9-Edited TILs: Targeting Intracellular Immune Checkpoint CISH in Metastatic Colorectal Cancer

In a first-in-human, single-institution phase I trial reported in The Lancet Oncology, Lou et al found that autologous tumor-infiltrating lymphocytes (TILs) genetically edited with CRISPR-Cas9 to target the intracellular immune checkpoint CISH were tolerable and showed evidence of activity in...

solid tumors
hematologic malignancies

Annual or Biennial Multicancer Early Detection Screening Improves Patient Outcomes

The addition of multi-cancer early detection screening using a single blood sample improved patient outcomes whether conducted on an annual or every 2-year basis, according to findings from a modelling study published in BMJ Open.   With earlier detection of disease progression, many cancers could...

colorectal cancer
lung cancer
solid tumors
symptom management

In Case You Missed It: Additional Abstracts of Interest From AACR

Thousands of forward-looking research studies defined the 2025 American Association for Cancer Research (AACR) Annual Meeting. Here, aside from our fuller coverage of key presentations in The ASCO Post, we offer a snapshot of a few additional abstracts that may be of interest to cancer researchers...

issues in oncology

Patterns in Oncology Drug Use After Accelerated Approval Is Withdrawn

The accelerated approval program of the U.S. Food and Drug Administration (FDA) allows certain medications to be marketed if they are indicated for serious disease and there has been preliminary evidence of the drug’s efficacy. Pharmaceutical companies must then conduct postapproval trials to...

breast cancer
issues in oncology

Collaborative Strategy Involving AI, Human Task-Sharing Could Help Minimize Mammogram Costs

When screening for breast cancer, the most effective strategy to utilize artificial intelligence (AI) may involve collaboration with human radiologists, according to a recent study published by Ahsen et al in Nature Communications. The findings could help shape how hospitals and clinics integrate...

issues in oncology

2024 Annual Report to the Nation on the Status of Cancer Finds Mortality Rates Continue to Decline

Overall deaths from cancer over the past 2 decades have steadily declined in both men and women in the United States, according to the 2024 Annual Report to the Nation on the Status of Cancer, which was published by Recinda L. Sherman, MPH, PhD, ODS-C, of the North American Association of Central...

hematologic malignancies

Off-the-Shelf Natural Killer CAR T-Cell Therapy Shows Efficacy in Small Study of Relapsed or Refractory Blood Cancers

The U.S. Food and Drug Administration (FDA) approved the first chimeric antigen receptor (CAR) T-cell therapy in 2017 to treat children with acute lymphoblastic leukemia.1 Over the past decade, other CAR T-cell therapies have been FDA approved to treat adults with blood cancers, including...

prostate cancer

Radiotherapy for Prostate Cancer: 2- vs 8-Week Course

The phase III HYPO-RT-PC trial has shown that a 2-week course of radiotherapy for localized prostate cancer—also known as ultra-hypofractionated radiotherapy—may be just as safe and effective as the traditional 8-week schedule—even 10 years after treatment. The findings were presented at the 2025...

gastroesophageal cancer

Early-Stage Stomach Cancer Diagnoses on the Rise

Stomach cancers are increasingly being diagnosed at less advanced, more treatable stages—a shift that marks major progress in detecting one of the deadliest forms of cancer, according to a study presented at Digestive Disease Week® (DDW) 2025 (Abstract Sa1374). “These trends suggest that...

gastrointestinal cancer

Anal Cancer Rates Rising Most Among Older White and Hispanic Women

Anal cancer has been steadily increasing in the United States, with the biggest jumps among older women, especially White and Hispanic women, a new study presented at Digestive Disease Week 2025 (Abstract 76) found. According to the investigators, this shift challenges assumptions about high-risk...

leukemia

Venetoclax-Based Therapy for Patients With Newly Diagnosed Acute Myeloid Leukemia

“Knowledge is like a lion; it cannot be gently embraced.” –South African Proverb Long-term efficacy and safety confirm that a hypomethylating agent and venetoclax is an improvement in the standard of care for patients with AML who are not eligible for intensive chemotherapy because of advanced age...

colorectal cancer

DDW 2025: 20-Year Screening Program Drives Down Colorectal Cancer Cases, Deaths

A 20-year initiative that offered flexible options for colorectal cancer screening at a major integrated health system doubled colorectal cancer screening rates, cut cancer incidence by a third, halved deaths, and brought racial differences in outcomes to nearly zero, according to a study that will ...

breast cancer

AACR 2025: Trends in Breast Cancer Incidence for Women Between the Ages of 20 and 49

Breast cancer deaths among women between the ages of 20 and 49 declined significantly across all breast cancer subtypes and racial/ethnic groups from 2010 to 2020, with marked declines starting after 2016, according to an analysis of data from the Surveillance, Epidemiology, and End Results (SEER)...

leukemia
hematologic malignancies
immunotherapy

AACR 2025: Off-the-Shelf Natural Killer CAR Therapy Active in Hematologic Malignancies

The U.S. Food and Drug Administration (FDA) approved the first chimeric antigen receptor (CAR) T-cell therapy in 2017 to treat children with acute lymphoblastic leukemia. Over the past decade, other CAR T-cell therapies have been FDA-approved to treat adults with blood cancers, including...

lung cancer
issues in oncology
genomics/genetics

AACR 2025: Zoldonrasib May Elicit Objective Responses in Patients With KRAS G12D–Mutated NSCLC

The oral KRAS G12D inhibitor zoldonrasib could provide clinical benefit in patients with previously treated non–small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D mutation, according to new findings presented by Arbour et al at the 2025 American Association for Cancer Research (AACR)...

colorectal cancer

AACR 2025: Use of ctDNA-Based Liquid Biopsy Assay in Resectable Colorectal Cancer

Interim results from the VICTORI study showed that an ultrasensitive circulating tumor DNA (ctDNA)-based liquid biopsy assay was effective in detecting signs of cancer recurrence prior to imaging and provided prognostic value within 1 month after surgery in patients with colorectal cancer. The...

issues in oncology
covid-19

Insights From Annual Report on Cancer Statistics

Overall deaths from cancer over the past 2 decades have steadily declined in both men and women in the United States, according to the 2024 Annual Report to the Nation on the Status of Cancer, published today by Sherman et al in Cancer. The report also found that although the incidence of cancer...

thyroid cancer

Early-Life Exposure to Environmental Carcinogens May Increase Risk of Pediatric Papillary Thyroid Cancer

Perinatal and early-life exposure to ambient fine particulate matter air pollution (PM2.5) and outdoor artificial light at night (O-ALAN) may be associated with a statistically significant increased risk of papillary thyroid cancer in children and young adults up to 19 years old, according to the...

issues in oncology

Link Between CT Scans and Future Cancer Incidence?

At current use and radiation dose levels, computed tomography (CT) scans may eventually account for 5% of all cancers annually, according to a recent modeling study published by Smith-Bindman et al in JAMA Internal Medicine. The danger is greatest for infants, followed by children and...

global cancer care

Most Pediatric Cancer Deaths Occur in Regions of Conflict

Almost 60% of all deaths from pediatric cancers occur in regions of armed conflict, according to the results of a study published in The Lancet Oncology.   Investigators from St. Jude Children’s Research Hospital, Duke University, and other institutions sought to reveal the relationship between...

issues in oncology
genomics/genetics
solid tumors
bladder cancer
skin cancer
lung cancer

Novel Strategy May Enhance Sensitivity, Accuracy of Monitoring Cancer in Blood Samples

A whole-genome sequencing–based, error-corrected method for detecting cancer from blood samples could be more sensitive and accurate in monitoring disease status posttreatment among patients with cancer compared with prior methods, according to a recent study published by Cheng et al in Nature...

colorectal cancer

FDA Approves Nivolumab With Ipilimumab for Unresectable or Metastatic MSI-H/dMMR Colorectal Cancer

On April 8, the U.S. Food and Drug Administration (FDA) approved the PD-1 inhibitor nivolumab (Opdivo) with the CTLA-4 inhibitor ipilimumab (Yervoy) for adult and pediatric patients aged 12 years and older with unresectable or metastatic microsatellite instability–high (MSI-H) or mismatch...

head and neck cancer

Characteristics of Nasopharyngeal Carcinoma in the United States

In a single-center study reported in JAMA Network Open, Alsavaf et al attempted to identify patient characteristics and treatment outcomes of nasopharyngeal carcinoma in the United States, a nonendemic region of the disease. Study Details The retrospective cohort study included patients with...

solid tumors
breast cancer
colorectal cancer
hepatobiliary cancer
issues in oncology

Awareness of Alcohol-Related Cancer Risks May Be Growing

An increasing proportion of the U.S. public may be aware of the link between consuming alcohol and the elevated risk of later developing cancer, according to a recent survey conducted by the University of Pennsylvania’s Annenberg Public Policy Center (APPC). Background On January 3, 2025, Vivek...

solid tumors
issues in oncology
colorectal cancer
breast cancer

Daily Physical Activity—Even at Light Intensities—May Reduce Cancer Risk

Investigators found that individuals who engaged in light- and moderate-to-vigorous–intensity physical activity daily had a lower risk of developing cancer compared with those who were more sedentary, according to a recent study published by Shreves et al in the British Journal of Sports Medicine....

gastrointestinal cancer

Active Surveillance vs Standard Surgery After Complete Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer

In a Dutch noninferiority phase III trial (SANO) reported in The Lancet Oncology, van der Wilk et al found that active surveillance was noninferior to standard surgery in terms of 2-year overall survival among patients with esophageal cancer who had a clinical complete response after neoadjuvant...

lung cancer
issues in oncology

Tobacco Control May Have Prevented Millions of Premature Lung Cancer Deaths in United States

Tobacco control–driven reductions in smoking prevalence may have helped avert over 3.8 million lung cancer–related deaths and gain just over 76 million years of life between 1970 and 2022 in the United States, according to a recent study published by Islami et al in CA: A Cancer Journal for...

integrative oncology

Building and Sharing Dietary Evidence in Cancer Care

Guest Editor’s Note: Several epidemiologic studies have shown an inverse association between healthy dietary patterns and the risk of chronic diseases including cancer. Patients are often interested in exploring different dietary interventions throughout the cancer continuum. However, concrete...

neuroendocrine tumors

FDA Approves Cabozantinib for pNET and epNET

Today, the U.S. Food and Drug Administration (FDA) approved the tyrosine kinase inhibitor cabozantinib (Cabometyx) for adult and pediatric patients aged 12 years and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors...

solid tumors
hematologic malignancies
issues in oncology

Sex Differences in Waist Circumference vs BMI as Risk Factors for Obesity-Related Cancers

Waist circumference may be a more effective risk marker for the development of obesity-related cancers than body mass index (BMI) in male but not female patients, according to new findings presented at the European Congress on Obesity (ECO) 2025. Background Body size and excess...

Virtual Reality Therapy May Improve Chemotherapy-Associated Side Effects

A study conducted by Stansel et al, which was published in the journal Clinical Journal of Oncology Nursing, highlighted the potential of virtual reality therapy to reduce patient stress, pain, and negative affect during chemotherapy sessions. The findings also appeared to support its delivery and...

issues in oncology

New Reports Assess Oncology Workforce Well-Being, Propose Solutions to Address Burnout

Physician burnout has increased significantly in the past decade, and organizational strategies are vital to improve physician well-being, according to new research from ASCO. This compilation includes reports on the state of professional well-being among oncologists in 2023, burnout trends among...

Advertisement

Advertisement




Advertisement